descriptionone
Sponsored by
Testing partnered content
Listen to this article
Stay ahead of every shift in generics and biosimilars.
More from Generics Bulletin
An abbreviated licensure pathway for biologics was created by the 2009 Biologics Price Competition and Innovation Act. Biologics demonstrated to be biosimilar to or interchangeable with FDA-approved products can use the 351(k) biologics license application pathway. Biosimilars BLAs submitted under the 351(k) pathway have a 12 month user fee goal for FDA action. Updated weekly.
UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - Clone
• By
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
• By
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
More from Partnered Content
Sponsored by :
As clinical trials grow more complex, execution pressures are changing where and how evidence is collected.
Primal Pictures
To make your document look professionally produced, Word provides header, footer, cover page, and text box designs that complement each other. For example, you can add a matching cover page, header, and sidebar. Click Insert and then choose the elements you want from the different galleries.
Sponsored by
sponsored by